This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMAG Pharmaceuticals (AMAG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is AMAG Pharmaceuticals (AMAG) Up 27.3% Since Last Earnings Report?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -93.94% and -15.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AMAG Pharmaceuticals (AMAG) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.
Alexion's Ultomiris Receives EU Approval for PNH in Adults
by Zacks Equity Research
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
All You Need to Know About AMAG Pharmaceuticals (AMAG) Rating Upgrade to Buy
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD Enters Agreement to Market Drugs Outside US
by Zacks Equity Research
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
AMAG Pharmaceuticals (AMAG) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for May 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -503.64% and -16.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments.
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
by Zacks Equity Research
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.
Why Is AMAG Pharmaceuticals (AMAG) Down 24.5% Since Last Earnings Report?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.
AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 38.78% and -2.17%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
by Zacks Equity Research
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.